VP45.23: Fetal sonographic follow‐up after maternal COVID‐19 infection: is there a matter of concern?

Abstract

Although there is no evidence of vertical transmission of COVID-19, fetal consequences of maternal COVID-19 remain unknown. The objective of the present study is to assess the impact of COVID-19 during pregnancy in terms of adverse perinatal outcomes, intrauterine growth restriction, fetal cardiac or neurosonographic abnormalities, and identify the association with maternal severity of COVID-19 disease or with gestational age at infection. Multicentric prospective cohort study including singleton pregnant women with diagnosis of SARS-CoV2 infection in 5 hospitals in Spain, starting from April 2020. Inclusion will continue until the end of the pandemic, with a minimum estimated sample size of 100 women. Maternal infection will be confirmed by nasopharyngeal PCR in the acute phase, or by further serologic test, and COVID-19 clinical presentation parameters will be collected. Once the patient has overcome the disease, ultrasound follow-up will be performed, including fetal growth assessment every 4 weeks, fetal neurosonography and echocardiographic evaluation in the third trimester, at least 4 weeks after maternal infection. All patients will be followed-up until delivery and perinatal outcome will be assessed. Analysis of associated factors related with echographic findings will be performed. We hypothesised that patients with severe COVID-19 disease have a higher risk of adverse perinatal outcome, fetal growth restriction, neurodevelopmental impairment and/or fetal cardiac function remodelling. To date a total of 52 patients have been included and results will be available by the end of September. This study will provide relevant information of fetal consequences of COVID-19 during pregnancy depending on maternal severity or trimester of infection.